Bill C-19, “An Act to implement certain provisions of the budget tabled in Parliament on April 7, 2022 and other measures” includes
measures directed to the term of copyright in Division 16 including “6. Except as otherwise expressly provided by this Act, the term for which copyright subsists is the life of the author, the remainder of the calendar year in which the author dies, and a period of 70 years following the end of that calendar year”;
changes to the College of Patent Agents and Trademark Agents Act in Division 17; and
replaces the term “prothonotary” with “associate judge” in Division 22.
Health Canada announced this afternoon, “…Health Canada will be moving forward with the implementation of the new basket of comparator countries and reduced reporting requirements for those medicines at lowest risk of excessive pricing. These [Amendments to the Patented Medicines Regulations] will come-into-force on July 1, 2022. The Government will not proceed with the Amendments related to the new price regulatory factors, nor with the requirements to file information net of all price adjustments.” Continue reading PMPRB→
CIPO has announced it is continuing and expanding its procedure to refer final rejections of patent applications to a single member of the PAB in certain circumstances if the rejection only relates to patentable subject matter (with some exceptions), s27(4) and the Patent Rules. CIPO is working to “increase efficiencies and reduce turnaround times” at the PAB. The 2019-2020 Annual Report identified 71 appeals to the PAB and 41 decisions issued.
In what is becoming a holiday tradition, the coming into force of amendments to the Patented Medicines Regulations has been again delayed by six months. The amendments were scheduled to come into force on January 1, 2022 having previously been scheduled for July 2021, January 2021, and July 2020 (see earlier post). The amendments generally relate to factors to be considered by the PMPRB for pricing patented medicines.
As mentioned last week, amendments to the Federal Courts Rules are being made, and were published in the Canada Gazette today for:
miscellaneous changes including expansion to Rule 3 to focus on ‘outcome’ and proportionality rather than ‘determination’, explicit powers to limit examinations (rule 87.1) and a rule specifically for motions in writing at the Federal Court of Appeal (rule 369.2), among other things.
Amendments to the Federal Courts Rules coming into force in January, have been registered. The amendments include expansion to Rule 3 to focus on ‘outcome’ and proportionality rather than ‘determination’, explicit powers to limit examinations (rule 87.1) and a rule specifically for motions in writing at the Federal Court of Appeal (rule 369.2), among other things.
The National Day for Truth and Reconciliation on September 30th has been incorporated into the Federal Courts Rules definition of “holiday”. The Federal Court issued a notice reminding litigants to take this holiday into account when computing deadlines and that hearings are being rescheduled.
Proposed amendments to the Patent Rules are published for consultation in the Canada Gazette to address patent term adjustment and other changes to streamline prosecution. The proposed amendments include excess claim fees, limits on office actions and requests for continued examination, updating rules on sequence listings and some miscellaneous amendments.
There are reports that the government has again delayed the coming-into-force of the substantive changes to the Patented Medicines Prices Review Board guildelines by six-months. The updates had been scheduled to come into force on July 1st. Continue reading PMPRB→
Canadian Intellectual Property
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.OkNo